Diamyd Medical announces today that one hundred study participants have been included in the ongoing US Phase III study, DiaPrevent. The global Phase III program with the company’s lead drug candidate Diamyd® has thereby enrolled more than 430 children newly diagnosed with type 1 diabetes in Europe and the USA.
Creating memories for families by sharing information relating to children and parents with regard to activities, products, school, home and more.
Diamyd Medical enrolls over 430 children with newly diagnosed type 1 diabetes in global Phase III program
- Login or register to post comments
- Feed: Pediatrics News Feed
- Original article